Abstract: The present invention relates to a novel-structured nucleic acid complex having a blood-brain barrier penetration ability and a composition comprising same and, more specifically, to a nucleic acid complex in which a bioactive nucleic acid is complementarily bound to a carrier peptide nucleic acid modified to be generally positively charged, and to a composition for blood-brain barrier penetration comprising same. The nucleic acid complex according to the present invention can penetrate the blood-brain barrier at excellent efficiency, and especially, the conjugation of a drug into the nucleic acid complex increases the blood-brain barrier penetration ability of the drug, and thus is very useful in treatment or diagnosis of diseases.

Abstract: A memory device may include a first data line driver circuit that generates a first reference voltage set based on a first code and a second code associated with a first data line, and determines bit values of the first input data received through the first data line, based on the first reference voltage set. A second data line driver circuit may similarly generate a second reference voltage set. The reference voltages may have levels based on a decision feedback equalization (DFE) technique to reduce bit errors otherwise caused by inter symbol interference.

Abstract: The present invention relates to a pharmaceutical composition that is for treating pancreatic cancer and contains a nucleic acid complex as an active ingredient, and more specifically, to a pharmaceutical composition that is for preventing or treating pancreatic cancer and contains a nucleic acid complex in which a bioactive peptide nucleic acid, having a sequence binding to the KRAS gene, and a carrier peptide nucleic acid are complementarily bound. The nucleic acid complex according to the present invention has excellent cell permeability and intracellular activity, and can effectively inhibit the expression of the KRAS gene and subtype genes thereof, and is thus useful for the prevention or treatment of pancreatic cancer.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating dementia, containing a nucleic acid complex in which a carrier peptide nucleic acid and a bioactive peptide nucleic acid having a sequence for binding to a NLRP3 gene are complementarily bound. The nucleic acid complex according to the present invention has a blood-brain barrier penetration ability and can effectively inhibit expression and phosphorylation of the protein of the NLRP3 gene and tau, which a lower-level gene, and thus is useful in the prevention or treatment of dementia.

Abstract: A nucleic acid complex having a novel structure, which may introduce a bioactive nucleic acid into cells, a composition for treating or diagnosing disease including the same, and a method of regulating target gene expression using the same, are described. The nucleic acid complex may include a bioactive nucleic acid, which includes a material for facilitating endosomal escape, and a carrier peptide nucleic acid, complementarily bound to each other, as useful in a composition for treating or diagnosing disease, or a composition for regulating target gene expression. Such nucleic acid complex may increase the stability of the bioactive nucleic acid, reduce loss of the bioactive nucleic acid, such as precipitation caused by self-aggregation, increase the intracellular delivery efficiency of the bioactive nucleic acid, and easily regulate target gene expression.

Abstract: The present invention relates to a composition for preventing or treating macular degeneration, containing a cell permeable nucleic acid complex as an active ingredient and, more specifically, to a pharmaceutical composition for preventing, ameliorating, or treating macular degeneration comprising, a cell-permeable nucleic acid complex containing a bioactive nucleic acid targeting an NLRP3 gene; and a carrier peptide nucleic acid which are complementarily bound to said bioactive nucleic acid, as an active ingredient. The cell permeable nucleic acid complex, in which the bioactive nucleic acid targeting the NLRP3 gene and the carrier peptide nucleic acid are complementarily bound to each other, according to the present invention, has high cell permeability and thus inhibits the expression of NLRP3 without direct injection, and thereby is useful for preventing, ameliorating, or treating macular degeneration.

Abstract: The present invention relates to a composition for preventing or treating skin diseases, comprising a skin-penetrating nucleic acid complex as an effective component, and more specifically, to a pharmaceutical composition or a cosmetic composition for preventing, alleviating, or treating atopic dermatitis, comprising a skin-penetrating nucleic acid complex in which a carrier peptide nucleic acid and a bioactive nucleic acid targeting TLR2 or IL-4R? are connected by complementary binding. The skin-penetrating nucleic acid complex according to the present invention, in which the carrier peptide nucleic acid and the bioactive nucleic acid targeting TLR2 or IL-4R? are connected by complementary binding, has high skin permeation and skin retention, and thus is useful in the prevention, alleviation or treatment of skin diseases such as atopic dermatitis.

Abstract: A skin-penetrating carrier containing a nucleic acid complex having a novel structure which introduces a bioactive nucleic acid into cells. Composition for diagnosing, preventing or treating disease and to a skin-penetrating carrier containing a nucleic acid complex in which a bioactive nucleic acid and a carrier peptide nucleic acid are complementarily bound to each other, and having skin permeability and skin retention ability. Skin-penetrating carrier containing nucleic acid complex having structure of Structural Formula (1) has both a skin penetration function of effectively delivering a large-molecular-weight drug and in vivo effectiveness. Carrier enables bioactive nucleic acids or various compounds to pass through the epidermis and dermis of the skin, thus enables external treatment by application to the skin surface.

Abstract: The present invention relates to a nucleic acid complex having a novel structure, which may introduce a bioactive nucleic acid into cells, a composition for treating or diagnosing disease comprising the same, and a method of regulating target gene expression using the same, and more particularly to a nucleic acid complex in which a bioactive nucleic acid, which comprises a material for facilitating endosomal escape, and a carrier peptide nucleic acid, are complementarily bound to each other, a composition for treating or diagnosing disease comprising the same, a composition for regulating target gene expression using the same, and a method of regulating target gene expression using the same.

Abstract: The present invention relates to a nucleic acid complex having a novel structure, which can introduce a bioactive nucleic acid into cells, a composition for treating and diagnosing disease, which comprises the same, and a method of regulating expression of a target gene using the same, and more particularly to a nucleic acid complex comprising a bioactive nucleic acid complementarily bound to a carrier peptide nucleic acid modified to be generally positively charged, a composition for treating and diagnosing disease, which comprises the same, and a method of regulating expression of a target gene using the same.

Abstract: The present invention relates to a nucleic acid complex having a novel structure, which can introduce a bioactive nucleic acid into cells, a composition for treating and diagnosing disease, which comprises the same, and a method of regulating expression of a target gene using the same, and more particularly to a nucleic acid complex comprising a bioactive nucleic acid complementarily bound to a carrier peptide nucleic acid modified to be generally positively charged, a composition for treating and diagnosing disease, which comprises the same, and a method of regulating expression of a target gene using the same.

Abstract: The present invention relates to a fusion protein having a TAL (transcription activator-like) effector (TALE) domain and a nucleotide cleavage domain, and more particularly, to the TAL effector nuclease comprising a TAL (transcription activator-like) effector (TALE) domain and a nucleotide cleavage domain, wherein the TALE domain includes one or more TALE-repeat modules, each of the TALE-repeat modules recognizing a single specific nucleic acid, and a use thereof.

Abstract: The present invention relates to methods and compositions useful for targeted cleavage and alteration of a genomic sequence, targeted cleavage followed by homologous recombination between an exogenous polynucleotide and a genomic sequence, or targeted cleavage followed by non-homologous end joining.